Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 5/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 4/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14801891 | 0.91 | RORC (0.35) | NR1H2RORCUSP2SMN1; SMN2GLS | |
| SCHEMBL14801888 | 0.91 | RORC (0.35) | NR1H2RORCUSP2SMN1; SMN2GLS | |
| SCHEMBL9943449 | 0.75 | NR1H2 (0.40) | NR1H2RORCUSP2SMN1; SMN2MEN1 | |
| SCHEMBL31695260 | 0.74 | NR1H2 (0.32) | NR1H2USP2SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL31444379 | 0.71 | NR1H2 (0.44) | NR1H2USP2SMN1; SMN2GLSRECQL | |
| SCHEMBL30755423 | 0.71 | NAMPT (0.33) | NR1H2USP2SMN1; SMN2GLSRECQL | |
| SCHEMBL31283122 | 0.71 | MEN1 (0.38) | NR1H2USP2SMN1; SMN2GLSRECQL | |
| SCHEMBL30987065 | 0.70 | NR1H2 (0.34) | NR1H2RORCUSP2SMN1; SMN2MAPT | |
| SCHEMBL30987202 | 0.70 | NR1H2 (0.34) | NR1H2RORCUSP2SMN1; SMN2MAPT | |
| SCHEMBL30455847 | 0.70 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2RECQLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758402-B9 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2758402-B1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER (US) | 2015-07-23 | — | — | US | disclosed |
| US-9040547-B2 | Pyrrolopyrimidine and purine derivatives | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | TYMP, DPYD, TYMS | NR1H2 4568/4885RORC 3322/4885USP2 4431/4885 |
| US-20150203502-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | TYMP, DPYD, TYMS | NR1H2 4568/4885RORC 3322/4885USP2 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.